PepGen Reports Favorable Safety and Splicing Trends for PGN-EDODM1 in Lowest Dose DM1 Trial

summarizeSummary

PepGen reported positive safety and promising splicing correction data from the lowest dose of its lead DM1 drug candidate, PGN-EDODM1, supporting continued development and extending its cash runway.

check_boxKey Events

• Favorable Safety Profile

  PGN-EDODM1 was generally well-tolerated in the 5 mg/kg cohort, with all adverse events reported as mild or moderate and no serious adverse events.

• Promising Splicing Correction

  The study showed a mean splicing correction of 7.3% (n=6) compared to placebo, with a more significant 22.9% correction observed when excluding one outlier patient (n=5).

• Positive vHOT Trends

  Promising trends were observed in the video hand opening test (vHOT) in the treatment group, suggesting potential functional benefits at higher doses.

• Extended Cash Runway

  The company expects its current cash to fund operations into the second half of 2027, providing financial stability for ongoing development.

auto_awesomeAnalysis

PepGen Inc. announced promising topline results from the lowest dose cohort of its Phase 2 FREEDOM2-DM1 trial. The lead candidate, PGN-EDODM1, demonstrated a favorable safety profile with all adverse events reported as mild or moderate and no serious adverse events. Crucially, the study showed a mean splicing correction of 22.9% (excluding one outlier) and promising trends in vHOT, supporting the drug's mechanism of action. While functional improvements were not observed at this lowest dose, the positive safety and biological activity data are significant, especially following the company's recent challenges including a partial clinical hold and a discontinued program. This data provides a critical positive signal for the ongoing development of their key remaining asset and extends their cash runway into 2H 2027. Investors will now focus on the upcoming 10 mg/kg cohort data in 2H 2026.